Australian Government

Department of Health

Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	325845	Curcuma Clinical
ARTG entry for	Medicine Listed	
Sponsor	Bio Concepts Pty Ltd	
Postal Address	PO Box 190, Banyo, Brisbane, QLD, 4014 Australia	
ARTG Start Date	1/11/2019	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Curcuma Clinical

Product Type	Single Medicine Product	**Effective Date**	21/09/2020

Permitted Indications

Antioxidant/Reduce free radicals formed in the body

Helps reduce/decrease free radical damage to body cells

Maintain/support general health and wellbeing

Anti-inflammatory/relieve inflammation in healthy adults

Decrease/reduce/relieve mild joint pain/soreness

Helps maintain/support bile secretion/flow

Indication Requirements

Label statement: If symptoms persist, talk to your health professional.

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis. Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.

Product presentation must only refer to mild joint symptoms.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

If symptoms persist, seek the advice of a healthcare professional.

Additional Product information

Pack Size/Poison information

Pack Size **Poison Schedule**

Components

1 . Formulation 1

Dosage Form	Capsule, hard
Route of Administration	Oral
Visual Identification	

Active Ingredients

Curcuma longa rhizome Extract dry concentrate standardised	**500 mg**
Equivalent: Curcuma longa (Dry)	15.625 g

Other Ingredients (Excipients)

colloidal anhydrous silica
disodium edetate
gellan gum
glycine
hypromellose
leucine
microcrystalline cellulose
potable water
potassium acetate

Public Summary